Ketosis-Prone Diabetes in African Americans: Predictive Markers, Underlying Mechanisms, and Treatment Outcomes: The Effects of Metformin vs. Sitagliptin on Beta-Cell Preservation in Obese Subjects With Ketosis-Prone Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Metformin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 29 Aug 2016 Results published in the Diabetes Care (2016).
- 17 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.